BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help
Search Results
Documents 1-5 out of 5 found
  Current Search:  endometrial: 127, stromal: 159, tumors: 241     
HTML
65%
Blocking Development of New Blood Vessels Augments Radiotherapy for Brain Tumors
High doses of radiotherapy fail to destroy glisoblatoma multiforme (GBM) brain tumors, but radiation therapy at lower doses has proven to cure the disease in an animal model when used in combination with treatment to prevent formation of new tumor blood vessels...
Biotech Daily:  Mar 11 2010 5:03PM
Matching: stromal tumors 		Find similar documents
HTML
65%
Management and Outcome of Gastrointestinal Stromal Tumors of the Duodenum
Chung JC et al.

Management and Outcome of Gastrointestinal Stromal Tumors of the Duodenum.

MDLinx:  Feb 15 2010 10:42AM
Matching: stromal tumors 		Find similar documents
HTML
65%
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
This analysis confirms a small PFS advantage of highdose imatinib, essentially a Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients.
MDLinx:  Feb 10 2010 10:34AM
Matching: stromal tumors 		Find similar documents
HTML
65%
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) f
Synta Pharmaceuticals Corp.

(NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090...

Stockwatch:  Dec 23 2009 1:52PM
Matching: stromal tumors 		Find similar documents
HTML
65%
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) f
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp.

(NASDAQ: SNTA - News), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is...

Business Wire via Yahoo!:  Dec 23 2009 1:47PM
Matching: stromal tumors 		Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.